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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.006The polyphenol compound resveratrol is reported to have multiple functions, including neuroprotection,
and no major adverse effects have been reported. Although the neuroprotective effects have been
associated with sirtuin 1 activation by resveratrol, the mechanisms by which resveratrol exerts such
functions are a matter of controversy. We examined whether resveratrol can be neuroprotective in two
models of multiple sclerosis: experimental autoimmune encephalomyelitis (EAE) and Theiler’s murine
encephalomyelitis virus-induced demyelinating disease (TMEV-IDD). EAE was induced in C57BL/6 mice,
which were fed a control diet or a diet containing resveratrol during either the induction or effector
phase or through the whole course of EAE. SJL/J mice were infected with TMEV and fed a control diet or
a diet containing resveratrol during the chronic phase of TMEV-IDD. In EAE, all groups of mice treated
with resveratrol had more severe clinical signs than the control group. In particular, resveratrol
treatment during the induction phase resulted in the most severe EAE, both clinically and histologically.
Similarly, in the viral model, the mice treated with resveratrol developed signiﬁcantly more severe
TMEV-IDD than the control group. Thus, surprisingly, the resveratrol treatment signiﬁcantly exacerbated
demyelination and inﬂammation without neuroprotection in the central nervous system in both models.
Our ﬁndings indicate that caution should be exercised in potential therapeutic applications of
resveratrol in human inﬂammatory demyelinating diseases, including multiple sclerosis. (Am J Pathol
2013, 183: 1390e1396; http://dx.doi.org/10.1016/j.ajpath.2013.07.006)Supported by the fellowships from the Malcolm Feist Cardiovascular
Research Endowment, Louisiana State University Health Sciences Center
(F.S.), by the NIH (National Institute of Neurological Disorders and Stroke
grant R21-NS059724, National Center for Research Resources grant 5P20-
RR018724, and National Institute of General Medical Sciences Centers of
Biomedical Research Excellence grant 8P20-GM103433 to I.T.), and by
National Multiple Sclerosis Society Pilot Research Award PP 1499 (I.T.).Resveratrol is a polyphenol compound found in a variety of
foods and beverages, including red grapes, peanuts, and red
wine.1 Resveratrol has been reported to have multiple
functions with anti-inﬂammatory, antioxidant, anti-aging,
and antiviral properties that could be beneﬁcial in diabetes
and cardiovascular diseases.2,3 Some of the effects of
resveratrol have been proposed to be exerted via activation
of sirtuin 1 (SIRT1), which prevents axonal degeneration.4
Increased SIRT1 activity by resveratrol was associated
with the suppression of apoptotic pathways and promoting
neuronal survival, although the activation by resveratrol has
lately been disputed.5 Three research groups demonstrated
that, in the SIRT1 assay, resveratrol activates SIRT1 when
Fluor de Lys peptide substrate with ﬂuorophore is used but
has no effect on SIRT1 activation when the Fluor de Lys
peptide substrate without ﬂuorophore is used.6e8 In all threestigative Pathology.
.reports, the authors concluded that resveratrol-mediated
SIRT1 activation is an experimental artifact.
Multiple sclerosis (MS) is an inﬂammatory demyelinating
disease with axonal degeneration in the central nervous
system (CNS).9,10 We examined the neuroprotective effects
of resveratrol in an autoimmune and a viral model of MS,
namely, experimental autoimmune encephalomyelitis (EAE)
and Theiler’s murine encephalomyelitis virus-induced de-
myelinating disease (TMEV-IDD).11,12 To our surprise,
Resveratrol Adverse Effects in MS Modelsresveratrol was not neuroprotective, but instead exacerbated
both EAE and TMEV-IDD. The lack of neuroprotective
effects of resveratrol in our study is consistent with the above
reports of failure to conﬁrm previously reported interactions
between resveratrol and SIRT1.6e8 Our ﬁndings indicate that
caution should be exercised in potential therapeutic applica-
tion of resveratrol in human diseases, including MS.
Materials and Methods
Resveratrol Treatment
Although an intake of resveratrol may be less constant via
chow than via oral gavage, resveratrol is more stable in chow
than in water,13 and we therefore administered the resveratrol
in chow. A diet containing resveratrol (Sigma-Aldrich, St.
Louis, MO) was prepared according to Banerjee et al.14 First,
50 g of a powder diet was weighed, then 55 mL of double-
distilled H2O were added to the powder diet and mixed
well. Next, 15 mL of 100% ethanol (control diet) or 100%
ethanol containing 0.02 g of resveratrol (for 0.04% in the
diet) was added to the chow and mixed well. For ethanol
evaporation, the chow was placed in a vacuum oven at 50C
overnight. Because resveratrol is sensitive to light,15e17 the
chow was kept away from light whenever possible and stored
in the dark at 4C.18 The mice were fed a control diet or a diet
containing resveratrol at various time points as described
below. A diet containing 0.04% resveratrol provided
approximately 20 mg/kg per day,2 which is the most standard
and effective dose reported by others.19e21 Although some
research groups have used a higher dose (100 mg/kg per day)
in animals, this higher dose corresponds to approximately 5
g/kg per day for humans, at which level kidney failure was
reported in a clinical trial for multiple myeloma.22 One
concern is that food intake of mice with full-blown EAE
might be lower, which would falsify the resveratrol dosage;
however, in the present study, the EAE mice fed a diet
containing resveratrol did not lose weight during the full-
blown EAE. We therefore concluded that there was no
signiﬁcant change in food intake at the peak of EAE.
Animal Experiments
EAE was induced in 6-week-old C57BL/6 mice (Harlan
Laboratories, Indianapolis, IN), using myelin oligodendro-
cyte glycoprotein (MOG)35-55 peptide (United Peptide,
Rockville, MD), as described previously.23 The mice were
fed a control diet or a diet containing resveratrol during the
induction (days 1 to 8; Early) or effector (days 14 to 23;
Late) phase, or through the whole course (days 1 to 63;
Whole) of EAE. Clinical scoring of EAE was as follows: 0,
no sign; 1, paralyzed tail; 2, mild hind-limb paresis; 3,
moderate hind-limb paralysis; 4, complete hind-limb para-
plegia; and 5, quadriplegia or moribund state.23
Five-week-old SJL/J mice (Jackson Laboratory, Bar
Harbor, ME) were infected intracerebrally with the DanielsThe American Journal of Pathology - ajp.amjpathol.org(DA) strain of TMEV, as described previously.24 The mice
were fed a control diet (DA alone) or a diet containing
resveratrol during the chronic phase (days 35 to 48;
Chronic) of TMEV infection. Clinical scoring of TMEV-
IDD was based on impairment of the righting reﬂex. The
proximal end of the mouse’s tail was grasped and twisted to
the right and then to the left, with scoring as follows: 0, the
mouse resists being turned over; 1, the mouse is ﬂipped onto
its back but immediately rights itself on one side; 1.5, the
mouse is ﬂipped onto its back but immediately rights itself
on both sides; 2, the mouse rights itself in 1 to 5 seconds; 3,
righting takes more than 5 seconds; and 4, the mouse cannot
right itself.24 All experimental procedures involving the
use of animals were reviewed and approved by the Institu-
tional Animal Care and Use Committee of Louisiana State
University Health Sciences Center and performed according
to the criteria outlined by the NIH.
Neuropathology
Mice were perfused with PBS followed by a 4% para-
formaldehyde solution (Sigma-Aldrich) in PBS. The CNS
tissues were harvested and ﬁxed with 4% paraformaldehyde.
The spinal cords were divided into 10 to 12 transversal
segments and brains into ﬁve coronal slabs before being
embedded in parafﬁn. Sections (4 mm thick) were stained with
Luxol Fast Blue (Solvent Blue 38; Sigma-Aldrich) for visual-
ization of myelin. For scoring of spinal cord sections, each
spinal cord section was divided into four quadrants (the ventral
funiculus, the dorsal funiculus, and each lateral funiculus), as
described previously.24,25 Any quadrant containing demyelin-
ation,meningitis, or perivascular cufﬁngwas given a score of 1
in that pathological class. The total number of positive quad-
rants for each pathological class was determined and then
divided by the total number of quadrants present on the slide
and multiplied by 100 to give the percent involvement for each
pathological class. An overall pathology score was also deter-
mined, by giving a positive score if any pathology was present
in the quadrant, and was calculated as percent involvement.
Brain pathology was scored for meningitis (0, no
meningitis; 1, mild cellular inﬁltration; 2, moderate cellular
inﬁltration; and 3, severe cellular inﬁltration), perivascular
cufﬁng (0, no cufﬁng; 1, 1 to 10 lesions; 2, 11 to 20 lesions;
3, 21 to 30 lesions; 4, 31 to 40 lesions; and 5, >40 lesions),
and demyelination (0, no demyelination; 1, mild demye-
lination; 2, moderate demyelination; and 3, severe demye-
lination). The three scores were combined, for a maximum
brain pathology score of 11 per mouse. Damaged axons
were visualized by immunohistochemistry with SMI 311
(Sternberger Monoclonal; Covance, Princeton, NJ), a cock-
tail of monoclonal antibodies (SMI 32, 33, 37, 38, and 39)
against nonphosphorylated neuroﬁlament, using the avidine
biotineperoxidase complex technique (Vector Laboratories,
Burlingame, CA) with 3,30-diaminobenzidine tetrahy-
drochloride as chromogen (Sigma-Aldrich) after antigen
retrieval in double-distilled H2O using a Digital Decloaking1391
Figure 1 Adverse effects of resveratrol in the EAE autoimmune model of
MS. C57BL/6 mice were sensitized with MOG35-55 on day 0 and were fed either
a control diet or a diet containing resveratrol on days1 to 8 (Early) or days 14
to 23 (Late) or days 1 to 63 (Whole). A: All three resveratrol-treated groups
developmore severe EAE, compared with the Control group, although all groups
had a similar disease onset. B: Control EAE mice have inactive demyelinating
lesions in the dorsal funiculus of the spinal cord. Mice treated with resveratrol
during the induction phase of EAE have more severe demyelination (arrow-
heads), meningitis (arrows), and active perivascular inﬂammation (paired
arrows), comparedwith control mice. Luxol fast blue staining. C: Mice fed a diet
containing resveratrol during the induction phase of EAE have signiﬁcantly
higher spinal cord pathology scores in demyelination, meningitis, perivascular
cufﬁng (indicative of inﬂammation), and overall pathology, compared with
mice fed a control diet. Mice treatedwith resveratrol during the whole course of
the experiment have signiﬁcantly higher scores in meningitis and overall
pathology, comparedwith controlmice.D: Brain pathology score does not differ
signiﬁcantly among the groups. Data are expressed asmeans (A) or as means
SEM (C andD). nZ 5 or 6 symptomatic mice per group. *P< 0.05, **P< 0.01,
ANOVA. Original magniﬁcation, 41. Scale barZ 100 mm.
Sato et alChamber I (Biocare Medical, Concord, CA) for 15 minutes
at 120C.26 The numbers of damaged axons were counted
under a light microscope using 10 to 12 transverse spinal
cord segments per mouse, as described previously.25
Statistical Analysis
Analysis of variance (ANOVA), Fisher’s exact test, and
t-test were performed using OriginPro 8.1 (OriginLab
Corporation, Northampton, MA) and StatView version 5.0
(SAS Institute, Cary, NC). Data are expressed as means 
SEM.
Results
Resveratrol Treatment Exacerbates MOG35-55eInduced
EAE
We ﬁrst determined whether resveratrol treatment could alter
EAE induced with MOG35-55. EAE mice were fed a control
diet or a diet containing resveratrol on days 1 to 8 (Early),
days 14 to 23 (Late), or days 1 to 63 (Whole). At approx-
imately 12 days after MOG sensitization, all groups of mice
started to develop clinical signs, including tail and hind-limb
paralysis; there was no signiﬁcant difference in the onset of
EAE between groups (P> 0.05, ANOVA) (Figure 1A). In all
four groups, mice exhibited disease progression and reached
disease peak 3 weeks after MOG sensitization. At 5 weeks
after MOG sensitization, most control EAE mice recovered
completely or remained mildly paralyzed during the 2
months observation period. In contrast, all three resveratrol
treatment groups recovered poorly and had signiﬁcantly
higher clinical scores than the control group at approximately
40 days after MOG sensitization; mean clinical scores on day
39 were 0.3 0.3 (Control), 3.0 0 (Early; P< 0.01 versus
Control), 1.9  0.4 (Late; P < 0.01 versus Control), and
2.0  0.5 (Whole; P < 0.01 versus Control). Mice in the
Early group experienced almost no remission and had lasting
severe EAE; mean clinical scores on day 61 were 0.3  0.3
(Control), 2.5  0.5 (Early; P < 0.01), 0.7  0.4 (Late), and
1.2  0.7 (Whole). During the chronic phase of EAE, the
clinical scores tended to be higher in the Late and Whole
groups, compared with the Control group, although the
difference did not reach statistical signiﬁcance (Figure 1A).
Of note, a few mice in the Early group did not develop EAE
[EAE incidence: 10/13 (77%) mice], whereas all of the mice
without resveratrol treatment during the induction phase
developed EAE [EAE incidence of 11/11 (100%) mice].
However, no statistical difference was found between the two
groups (P Z 0.228, Fisher’s exact test). Thus, resveratrol
might be useful only as a prophylactic, but not for therapeutic
use in autoimmune-mediated demyelinating diseases.
At 2 months after EAE induction, we sacriﬁced symp-
tomatic mice and compared the neuropathology of symp-
tomatic mice between the groups. In the spinal cord of the
Control group, inactive demyelinating lesions in the white1392matter with meningitis and axonal degeneration were detec-
ted by Luxol fast blue staining for myelin (Figure 1B) and by
immunohistochemistry against nonphosphorylated neuro-
ﬁlament as a marker of axonal degeneration (Figure 2A).
Consistent with the clinical signs, the Early group had severeajp.amjpathol.org - The American Journal of Pathology
Figure 2 Axonal degeneration, 2 months after EAE induction. EAE mice
were given a control diet or a diet containing resveratrol on days 1 to 8
(Early), days 14 to 23 (Late), or days 1 to 63 (Whole). A: Immunohisto-
chemistry for nonphosphorylated neuroﬁlament reveals higher levels of axonal
damage (arrows) in the Early group than in the Control group. Boxed regions
are shown at higher magniﬁcation in the corresponding inset. B: Higher
numbers of nonphosphorylated neuroﬁlament-positive damaged axons are
detected in the spinal cord of mice fed a diet containing resveratrol during the
induction phase of EAE, compared with control mice. Data are expressed as
means SEM. nZ 5 or 6 symptomatic mice per group. **P < 0.01, ANOVA.
Original magniﬁcation: 83;115 (insets). Scale bars: 50 mm (A).
Resveratrol Adverse Effects in MS Modelsactive inﬂammatory demyelinating lesions with axonal
degeneration (Figures 1B and 2A). The pathology scores and
numbers of damaged axons in the spinal cord were signiﬁ-
cantly higher in the Early group than in the Control group
(Figures 1C and 2B). The Whole group had more severe
demyelination and meningitis than the Control group, but the
levels of axonal degeneration were similar. No signiﬁcant
difference was seen in neuropathology between the Control
and the Late groups. Although the brain pathology scores were
higher in the Early and Whole groups than in the Control and
Late groups, the scores were mild in all groups, and there was
no signiﬁcant difference between groups (Figure 1D). We also
compared the levels of MOG35-55especiﬁc lymphoprolifer-
ative responses and proinﬂammatory cytokine production
between the groups and found no signiﬁcant differences
(Supplemental Figure S1). Thus, even though resveratrol has
been reported to have anti-inﬂammatory properties,3 in the
present study resveratrol did not suppress autoimmune
responses.
Resveratrol Treatment Exacerbates TMEV-IDD
We next examined whether resveratrol treatment has
suppressive effects on a viral model of MS, TMEV-IDD.27
We treated TMEV-infected mice during the chronic phase,
in which mice develop inﬂammatory demyelinating disease
at approximately 1 month after infection. Mice were infectedThe American Journal of Pathology - ajp.amjpathol.orgwith the DA strain of TMEV on day 0 and were fed a control
diet (DA alone) or a diet containing resveratrol from day 35 to
day 48 (Chronic). Beginning approximately 1 month after
infection, both groups displayed impairment of righting
reﬂexes. The Chronic group had signiﬁcantly higher righting
reﬂex scores than the DA alone group; mean clinical scores
on day 48 were 1.4 0.1 and 2.1 0.2 for the DA alone and
Chronic group, respectively (P < 0.05, t-test) (Figure 3A).
Histologically, mice treated with resveratrol developed
signiﬁcantly more severe demyelination, meningitis, and
perivascular cufﬁng in the spinal cord, compared with control
mice (Figure 3, B and C). Regardless of treatment, both
groups of mice developed severe axonal degeneration
(Figure 4A), and quantiﬁcation of damaged axons revealed
no signiﬁcant difference between the two groups (P > 0.05,
t-test) (Figure 4B). In the brain, the Chronic group had higher
pathology scores than the DA alone group, although the
difference did not reach statistical signiﬁcance (Figure 3D).
To determine whether resveratrol treatment modulated the
immune responses in TMEV-IDD, we measured the levels of
TMEV-speciﬁc lymphoproliferation and proinﬂammatory
cytokine production in each group. Although no signiﬁcant
difference was seen in a lymphoproliferation assay between
the two groups, resveratrol treatment during the chronic
phase of TMEV infection resulted in approximately twofold
increased IL-17 production and approximately twofold
decreased interferon (IFN)-g production (Supplemental
Figure S2).
We also examined whether resveratrol has prophylactic
effects on TMEV-IDD. Mice were infected with the DA
strain of TMEV on day 0 and were fed a control diet (DA
alone) or a diet containing resveratrol during the acute (days
0 to 14; Acute) or subclinical (days 21 to 35; Subclinical)
phase of TMEV infection. Both clinically and histologically,
the Subclinical group tended to have more severe disease
signs than the DA alone group, although the difference did
not reach statistical signiﬁcance (Supplemental Figures S3
and S4). Using hyperimmune serum against TMEV, we
observed similar levels and distributions of viral antigen-
positive cells in the spinal cord in the three groups
(Supplemental Figure S4). We also examined the effect of
resveratrol treatment on immune responses in TMEV-IDD
and found that the levels of TMEV-speciﬁc lymphoproli-
ferative and antibody responses were similar in the three
groups (Supplemental Figure S5). Production of both IL-17
and IFN-g was lower in the Acute and Subclinical groups
than in the DA-alone group, although the difference did not
reach statistical signiﬁcance (Supplemental Figure S5).
Resveratrol Treatment Is Not Neuroprotective in
Infection with a Neurovirulent Strain of TMEV
In the above experiments, we did not observe a neuro-
protective effect of the resveratrol treatment. One explana-
tion could be enhancement of inﬂammation in the CNS,
which might mask the neuroprotective effects of resveratrol.1393
Figure 4 Axonal degeneration, 2 months after TMEV infection. SJL/J
micewere infectedwith theDA strain of TMEV and fed a control diet (DA alone,
black bar) or a diet containing resveratrol from day 35 to day 48 (Chronic,
white bar).A: Levels of damaged axons (arrows) in the spinal cord are similar
in the two groups. Immunohistochemistry for nonphosphorylated neuro-
ﬁlament. B: Nonphosphorylated neuroﬁlament-positive damaged axons in
the spinal cord are similar in the two groups. Data are expressed as means
SEM.nZ8miceper group. Originalmagniﬁcation,83. Scale bars: 50mm(A).
Figure 3 Adverse effects of resveratrol in the TMEV viral model of MS.
SJL/J mice were infected intracerebrally with 2  105 PFU of the DA strain
of TMEV on day 0 and were fed a control diet (DA alone, black bars) or a diet
containing resveratrol from day 35 to day 48 (Chronic, white bars). A: The
TMEV-infected mice treated with a resveratrol diet develop more severe
clinical signs than mice on the control diet. B: Mice treated with a resver-
atrol diet have more severe demyelination (arrowheads), meningitis
(arrows), and active perivascular inﬂammation (paired arrows) than mice
on the control diet. Luxol fast blue staining. C: The TMEV-infected mice fed
resveratrol have signiﬁcantly higher pathology scores in demyelination,
meningitis, and perivascular cufﬁng (inﬂammation) than mice fed a control
diet. D: There is a small but nonsigniﬁcant difference in brain pathology
scores between the two groups. Data are expressed as means (A) or as
means  SEM (C and D). n Z 8 mice per group. *P < 0.05, **P < 0.01,
ANOVA. Original magniﬁcation, 42. Scale bars: 100 mm (B).
Sato et alTo address this possibility, we used the GDVII strain of
TMEV, which is highly neurovirulent.24 Unlike the DA
virus, GDVII virus induces neurodegeneration without
induction of TMEV-speciﬁc immune responses.26 Thus,
GDVII virus infection can be used to determine whether
resveratrol can suppress neurodegeneration caused by direct
viral infection (not by immunopathology). Mice were
infected with 1 to 1000 plaque-forming units (PFU) of
GDVII virus and were fed a control diet (GDVII alone) or
a diet containing resveratrol (GDVII-resveratrol). Regardless1394of resveratrol treatment, all mice infected with 100 or 1000
PFU of GDVII virus started to exhibit encephalitic signs,
such as weight loss, rufﬂed fur, and a hunched posture, at
approximately day 6 and all died within 10 days of infection
(Supplemental Table S1). A small number of mice infected
with a low dose (1 or 10 PFU) of GDVII virus survived the
infection. Both mortality and survival period were similar in
the two groups. The lethal dose (LD)50 was similar in mice
fed a control diet and mice treated with resveratrol (GDVII
alone, 2.6 PFU; GDVII-resveratrol, 3.8 PFU).
As an indicator of neurodegeneration, we compared
the levels of neuronal apoptosis and axonal degeneration
between the two groups. Using the TUNELmethod,we found
that all symptomatic mice had large numbers of apoptotic
neurons (particularly in the cerebral cortex, thalamus, and
hippocampus), regardless of treatment (Supplemental
Figure S6A). Quantiﬁcation of apoptotic neurons in the
brain revealed no statistical difference in the number of
TUNEL-positive cells between the two groups (P > 0.05,
t-test) (Supplemental Table S2). Regardless of treatment,
all symptomatic mice had large numbers of damaged
axons in the white matter of the spinal cord (Supplemental
Figure S6A). Quantiﬁcation of damaged axons revealed no
signiﬁcant difference in the levels of axonal degeneration
between the two groups (P > 0.05, t-test) (Supplemental
Figure S6B). We also scored the severity of brain pathology
based on the levels of meningitis and perivascular inﬂam-
mation. The brain pathology scores were similar in the two
groups (Supplemental Figure S6C).ajp.amjpathol.org - The American Journal of Pathology
Resveratrol Adverse Effects in MS ModelsDiscussion
We demonstrated that the resveratrol treatment exacerbated
demyelinating disease with no neuroprotection in both EAE
and TMEV-IDD, although the precise mechanism is unclear.
Experimentally, animal studies for cardiovascular disease
suggest that resveratrol exerts a vasodilation effect by
improving function of endothelial cells, which form the inner
wall of blood vessels.28 The expansion of blood vessels
enhances blood ﬂow volume and reduces blood ﬂow
velocity. Theoretically, these processes facilitate tethering,
rolling, and ﬁrm adhesion of circulating inﬂammatory cells to
endothelia, leading to the transmigration of inﬂammatory
cells across the bloodebrain barrier and into the CNS.29 In
the present study, resveratrol treatment resulted in higher
pathology scores for meningitis and perivascular cufﬁng in
both EAE and TMEV-IDD. This suggests that the vasodi-
lation effects by resveratrol enhanced inﬁltration of inﬂam-
matory cells into the CNS. Inﬂammatory cell inﬁltration into
the CNS has been suggested to play a key role in the path-
ogenesis of MS,30 because large numbers of inﬂammatory
cells inﬁltrate across the bloodebrain barrier in active lesions
from patients with MS.31 Furthermore, in MS, injection of
natalizumab (Tysabri; Biogen Idec, Weston, MA), a mono-
clonal antibody against a4-integrin [very late antigen 4
(VLA-4)], can inhibit migration of inﬂammatory cells into
the CNS, reducing the severity of disease.29 Similar to the
case of MS, in EAE the blockade of migration of inﬂam-
matory cells into the CNS has been shown to improve clinical
signs.32,33 Thus, the exacerbation of both EAE and TMEV-
IDD by resveratrol treatment observed in the present study
could be due to enhanced inﬁltration across the bloodebrain
barrier of inﬂammatory cells, accompanied by vasodilation.
We also found no signiﬁcant differences in immune
responses between control and resveratrol-treated EAE mice.
Although resveratrol has been tested in several different
conditions in EAE,34e36 resveratrol studies in EAE have not
shown consistent outcomes. Singh et al34 and Imler et al35
demonstrated that EAE clinical scores were lower in mice
treated with resveratrol, compared with control mice, although
resveratrol treatment altered proinﬂammatory cytokine
production either positively or negatively, depending on the
disease course or the dose of resveratrol. It is unknownwhether
decreased clinical signs correlate with neuroprotection by
resveratrol, because axonal damage was not examined in these
studies. On the other hand, Fonseca-Kelly et al36 demonstrated
that a high dose (250 mg/kg per day) of resveratrol delayed the
onset of EAE, but a low dose (100 mg/kg per day) had no
effect36; however, both resveratrol treatments neither am-
eliorated CNS pathology nor suppressed immune responses,
although resveratrol treatments protected from the loss of
retinal ganglion cells, which are the neurons forming the optic
nerve. The different effects of resveratrol on EAEmay be due to
differences in antigens and animals. For EAE induction, Imler
et al35 sensitized SJL/J mice with myelin proteolipid protein
(PLP)139-151, whereas other research groups,
33,35 includingThe American Journal of Pathology - ajp.amjpathol.orgour own group, sensitized C57BL/6 mice with MOG35-55. In
MOG-induced EAE, different groups used different con-
centrations of MOG and pertussis toxin. Thus, further research
is needed to determine the optimal concentration of resveratrol
and what factors may result in deleterious effects.
Resveratrol has been shown to have antiviral effects on
some viruses relevant to MS, including herpes simplex virus
(HSV) and EpsteineBarr virus (EBV),37,38 although the
exact mechanisms remain unclear. In HSV infection,
resveratrol inhibited viral replication by regulation of the
nuclear factor-kB (NF-kB) pathway in vitro.39 Resveratrol
treatment modulated EBV early antigen induction in vitro.40
In the present study, however, with the DA strain of TMEV
infection, resveratrol-treated mice had levels of viral
antigen-positive cells in the spinal cord similar to those of
control mice. Furthermore, resveratrol treatment did not
substantially alter LD50 titers in mice infected with the
GDVII strain of TMEV. Thus, resveratrol did not have
antiviral effects in TMEV infection.
In conclusion, we demonstrated that resveratrol treatment
profoundly exacerbated demyelinating disease with
enhanced CNS inﬂammation in EAE and TMEV-IDD, two
animal models of MS. Although resveratrol has not been
reported to have major adverse effects, GlaxoSmithKline
reported that the safety of a proprietary formulation of
resveratrol known as SRT501 was questioned in a clinical
trial for patients with multiple myeloma.22 In this trial,
several patients treated with SRT501 experienced kidney
failure, although it is unclear whether the kidney failure was
due to SRT501 treatment or was a natural consequence of
the disease. Nonetheless, resveratrol may have detrimental
effects in some disease conditions and its use should be
discouraged for MS patients, pending further research.
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